指南与共识眼底病与葡萄膜炎

Pegcetacoplan治疗与地图样萎缩24个月共识特征分析

Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
指南 / 共识 · JAMA Ophthalmol · 2024-01-01

该研究为OAKS和DERBY两项3期随机双盲假注射对照研究的事后分析,纳入936例地图样萎缩患者,比较pegcetacoplan每月或隔月注射与假注射对SD-OCT共识终点的影响。结果显示pegcetacoplan可降低视网膜色素上皮和外层视网膜萎缩面积增长率,每月给药差异为-0.86 mm²(95%CI -1.15至-0.57,P<.001),隔月给药差异为-0.69 mm²(95%CI -0.98至-0.39,P<.001)。

要点

  • pegcetacoplan每月和隔月注射均与24个月内SD-OCT生物标志物增长速率降低相关。
  • 第24个月时,每月组与合并假注射组相比,视网膜色素上皮和外层视网膜萎缩面积变化差异为-0.86 mm²(P<.001)。
  • 旁中心凹和中心凹周围区域观察到更强的关联。

核心结论

  • pegcetacoplan可能对地图样萎缩的发展有潜在影响,包括对视网膜色素上皮和光感受器的潜在影响。

研究设计与样本

  • 研究为OAKS和DERBY两项平行3期研究的事后分析,共纳入936例受试者的11614份SD-OCT体积数据。
  • OAKS和DERBY为24个月、多中心、随机、双盲、假注射对照研究,于2018年8月至2020年7月进行。
  • 纳入标准为眼底自发荧光成像上地图样萎缩总面积2.5至17.5 mm²(多灶者至少1个病灶≥1.25 mm²)的成人患者。

主要发现

  • 第24个月时,每月pegcetacoplan组与合并假注射组相比,视网膜色素上皮和外层视网膜萎缩面积较基线最小二乘均值变化差异为-0.86 mm²(95%CI -1.15至-0.57,P<.001)。
  • 第24个月时,隔月pegcetacoplan组与合并假注射组相比,相应差异为-0.69 mm²(95%CI -0.98至-0.39,P<.001)。
  • 第24个月时,每月pegcetacoplan组与隔月pegcetacoplan组相比,差异为-0.17 mm²(95%CI -0.43至0.08,P=.17),未达统计学显著。
  • 从第3个月至第24个月各时间点均检测到pegcetacoplan组与假注射组之间视网膜色素上皮和外层视网膜萎缩面积变化的差异。
  • 在旁中心凹和中心凹周围区域,每月和隔月pegcetacoplan组均观察到更强的关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite widespread availability and consensus on its advantages for detailed imaging of geographic atrophy (GA), spectral-domain optical coherence tomography (SD-OCT) might benefit from automated quantitative OCT analyses in GA diagnosis, monitoring, and reporting of its landmark clinical trials. OBJECTIVE: To analyze the association between pegcetacoplan and consensus GA SD-OCT end points. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of 11 614 SD-OCT volumes from 936 of the 1258 participants in 2 parallel phase 3 studies, the Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OAKS) and Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (DERBY). OAKS and DERBY were 24-month, multicenter, randomized, double-masked, sham-controlled studies conducted from August 2018 to July 2020 among adults with GA with total area 2.5 to 17.5 mm2 on fundus autofluorescence imaging (if multifocal, at least 1 lesion ≥1.25 mm2). This analysis was conducted from September to December 2023. INTERVENTIONS: Study participants received pegcetacoplan, 15 mg per 0.1-mL intravitreal injection, monthly or every other month, or sham injection monthly or every other month. MAIN OUTCOMES AND MEASURES: The primary end point was the least squares mean change from baseline in area of retinal pigment epithelium and outer retinal atrophy in each of the 3 treatment arms (pegcetacoplan monthly, pegcetacoplan every other month, and pooled sham [sham monthly and sham every other month]) at 24 months. Feature-specific area analysis was conducted by Early Treatment Diabetic Retinopathy Study (ETDRS) regions of interest (ie, foveal, parafoveal, and perifoveal). RESULTS: Among 936 participants, the mean (SD) age was 78.5 (7.22) years, and 570 participants (60.9%) were female. Pegcetacoplan, but not sham treatment, was associated with reduced growth rates of SD-OCT biomarkers for GA for up to 24 months. Reductions vs sham in least squares mean (SE) change from baseline of retinal pigment epithelium and outer retinal atrophy area were detectable at every time point from 3 through 24 months (least squares mean difference vs pooled sham at month 24, pegcetacoplan monthly: -0.86 mm2; 95% CI, -1.15 to -0.57; P < .001; pegcetacoplan every other month: -0.69 mm2; 95% CI, -0.98 to -0.39; P < .001). This association was more pronounced with more frequent dosing (pegcetacoplan monthly vs pegcetacoplan every other month at month 24: -0.17 mm2; 95% CI, -0.43 to 0.08; P = .17). Stronger associations were observed in the parafoveal and perifoveal regions for both pegcetacoplan monthly and pegcetacoplan every other month. CONCLUSIONS AND RELEVANCE: These findings offer additional insight into the potential effects of pegcetacoplan on the development of GA, including potential effects on the retinal pigment epithelium and photoreceptors. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03525600 and NCT03525613.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fu DJ, Bagga P, Naik G, et al. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. JAMA Ophthalmol. 2024. PMID: 38722644. doi:10.1001/jamaophthalmol.2024.1269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。